Symbol
| SLC2A4
| contributors: mct - updated : 22-06-2018
|
HGNC name
| solute carrier family 2 (facilitated glucose transporter), member 4
|
HGNC id
| 11009
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
|  
| --low
|  
|
in adipose tissue but preserved in muscle in insuline-resitant states such as obesity and type 2 diabetes | |
Susceptibility
|
non insulin dependent diabetes mellitus (type 2) |
Variant & Polymorphism
| polymorphic variant |
|
|
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
diabete | type 2 | | |
promising target for pharmacogenomics of insulin resistance | cancer | | | |
therapeutic strategy entailing selective SLC2A4, SLC2A11, SLC2A8 inhibition to specifically target aberrant glucose metabolism in cancer |
| | | |